DICE Therapeutics (NASDAQ:DICE) reported quarterly losses of $(0.55) per share. This is a 74.42 percent increase over losses of $(2.15) per share from the same period last year.
Morgan Stanley Downgrades AppLovin to Equal-Weight, Lowers Price Target to $20
Morgan Stanley analyst Matthew Cost downgrades AppLovin (NASDAQ:APP) from Overweight to Equal-Weight and lowers the price target from $35 to $20.